Neophyr (Nitric Oxide)

Nitric oxide released from Neophyr activates soluble guanylate cyclase in the smooth muscle of pulmonary arteries. This raises cyclic GMP levels, causing muscle relaxation and selective dilation of the lung vessels, which lowers pulmonary arterial pressure without causing systemic vasodilation.

The dosage of Neophyr is determined by the prescribing clinician based on the patient’s age, weight, severity of disease, and response to therapy. The prescriber sets the inhaled concentration and duration according to established clinical protocols.

Safety data for inhaled nitric oxide in pregnancy and lactation are limited. The product should only be used if the potential benefit justifies any potential risk to the fetus or infant, and the decision must be made by a qualified healthcare professional.

To request Neophyr, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain needs), and import documentation.

Neophyr delivers nitric oxide directly to the lungs, providing rapid and selective pulmonary vasodilation. Compared with systemic agents such as phosphodiesterase‑5 inhibitors, it has a quicker onset and fewer systemic effects, but requires specialized delivery equipment and careful monitoring.

Neophyr cylinders should be stored at ambient temperature, kept upright, and protected from heat, direct sunlight, and physical damage. Ensure the cylinder valve is closed when not in use and follow local regulations for medical gas storage.

Neophyr is administered via a calibrated inhalation system that delivers a controlled concentration of nitric oxide gas to the patient’s airway. The device is connected to the patient’s ventilator or breathing circuit, and the clinician adjusts the flow to achieve the prescribed dose.

Serious risks include methemoglobinemia, severe hypotension, pulmonary edema, and allergic reactions such as anaphylaxis. Continuous monitoring of blood pressure, oxygen saturation, and methemoglobin levels is essential to detect and manage these complications promptly.

Neophyr should be avoided in patients with known hypersensitivity to nitric oxide, those with severe cardiovascular instability, or individuals receiving contraindicated medications such as phosphodiesterase‑5 inhibitors without careful supervision. Clinical judgment is required for each case.